32122-23-9

Basic information

• Product Name: 1-bromocyclobutane-1-carboxylic acid
• Synonyms: 1-bromocyclobutane-1-carboxylic acid;1-BroMocyclobutanecarboxylic acid;NSC 179441;Cyclobutanecarboxylicacid, 1-broMo-;1-bromocyclobutane carbocylic acid
• CAS NO: 32122-23-9
• Molecular Formula: C₅H₇BrO₂
• Molecular Weight: 179.01
• Mol File: 32122-23-9.mol

Chemical Properties

• Melting Point: 48℃
• Boiling Point: 249℃
• Flash Point: 104℃
• Appearance: /
• Density: 1.864
• Vapor Pressure: 0.00748mmHg at 25°C
• Refractive Index: 1.586
• PKA: 2.94±0.20(Predicted)
• CAS DataBase Reference: 1-bromocyclobutane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromocyclobutane-1-carboxylic acid(32122-23-9)
• EPA Substance Registry System: 1-bromocyclobutane-1-carboxylic acid(32122-23-9)

Safety Data

• Hazardous Substances Data: 32122-23-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Bromocyclobutane-1-carboxylic acid is used as a building block in organic synthesis for the preparation of various organic molecules. Its unique structure and reactivity allow for the formation of new chemical bonds and the synthesis of complex organic compounds.
Used in Pharmaceutical Research:
1-Bromocyclobutane-1-carboxylic acid is used as a starting material in pharmaceutical research for the development of drug candidates. Its specific reactivity and properties can be exploited to create novel compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
1-Bromocyclobutane-1-carboxylic acid is used as a reagent in medicinal chemistry for the synthesis of bioactive molecules. Its unique structure and reactivity can contribute to the discovery of new drugs and therapeutic agents.
Used in Drug Discovery:
1-Bromocyclobutane-1-carboxylic acid is used as a component in drug discovery processes, where its unique properties can be utilized to identify and optimize potential drug candidates with desired pharmacological properties.

InChI:InChI=1/C5H7BrO2/c6-5(4(7)8)2-1-3-5/h1-3H2,(H,7,8)

Upstream product

• 3721-95-7 Cyclobutanecarboxylic acid 
• 35120-18-4 ethyl 1-bromocyclobutane-1-carboxylate 
• 51175-79-2 methyl α-bromocyclobutanecarboxylate 
• 542-28-9 3,4,5,6-tetrahydro-2H-pyran-2-one 

Downstream Products

• 23519-90-6 1-cyclobutenecarboxylic acid 
• 41248-13-9 1-hydroxycyclobutane-1-carboxylic acid 
• 2770-58-3 1-bromo-N-phenylcyclobutane-1-carboxamide 
• 956104-40-8 ARN-509 

Relevant articles and documents

A new cyclobutane ring contraction: The base-induced rearrangement of an a-bromocyclobutanecarboxylic ester

Contrary to previous reports, reactions of methyl α-bromocyclobutanecaiboxylate 6b with potassium hydroxide or carbonate lead exclusively to 1-(hydroxymethyl)cyclopropanecarboxylic acid 7.

2-(1-bromocyclobutyl) pyridine and synthesis method thereof

The invention belongs to the technical field of organic synthesis, and relates to 2- (1-bromocyclobutyl) pyridine and a synthesis method thereof. The 2 -(-1bromocyclobutyl) pyridine can be used as a medical intermediate, and the synthetic method of the compound comprises the following steps: by taking tetrahydropyrane- 2-ketone as a raw material, carrying out nine steps of reactions including substitution, ring closing, hydrolysis, substitution, substitution, reduction, grignard, substitution and substitution to prepare the 2- (-1bromocyclobutyl) pyridine, so that the synthetic route is simple, the cost is low, and the efficiency is high.

SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

The present invention relates to novel spirocyclic compounds of formulas (1) and (2) which act as modulators of indoleamine 2,3-dioxygenase (ID01) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The invention further relates to pharmaceutical compositions comprising the novel compounds.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

(DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES

The invention relates to 5,6 - dihydropyrrolo [2,1-a] isoquinoline and pyrrolo[2,1-a] isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.

A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: Synthesis and structure-activity relationships

A series of 7β-[2-(2-aminothiazol-4-yl)-2-(Z)-(carboxymethoxyimino)acetamido]cephalosporins bearing a 1-(substituted)-1H-pyrrolo[3,2-b]pyridinium group at C-3′ position was synthesized and their in vitro antibacterial activities against Pseudomonas aeruginosa and other Gram-negative pathogens were evaluated. Among the cephalosporins prepared, 7β-[2-(2-amino-5-chlorothiazol-4yl)-2(Z)-((S)-1-carboxyethoxyimino)acetamido]cephalosporins (42d) showed potent antibacterial activities against P. aeruginosa and other Gram-negative pathogens including the strains which produce class C β-lactamase and extended spectrum β-lactamase (ESBL). These results imply that both the Cl atom on the C-7 aminothiazole moiety and the α-substituent at the iminoether moiety are essential for the stability against β-lactamase and the potent activity against Gram-negative bacteria including P. aeruginosa.

Homolytic aromatic substitution: A radical approach towards the synthesis of 5-azaoxindoles

A range of 5-azaoxindoles have been synthesised employing homolytic aromatic substitution onto pyridine as the pivotal step.